Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 2/3 2Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Precancerous Conditions 1Polyps 1Neoplastic Syndromes, Hereditary 1Mouth Neoplasms 1Keratosis, Actinic 1Intestinal Neoplasms 1Intestinal Diseases 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Duodenal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Adenomatous Polyps 1Adenomatous Polyposis Coli 1Adenoma 1

Interventions

Docetaxel 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Prednisone 5Androgen Antagonists 5gallium 68 PSMA-11 4enzalutamide 3bicalutamide 3Triptorelin Pamoate 3Radiosurgery 3Leuprolide 3Goserelin 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Zoledronic Acid 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Mitoxantrone 2Flutamide 2Celecoxib 2Abiraterone Acetate 2satraplatin 1relugolix 1pertuzumab 1nilutamide 1maltodextrin 1luprolide acetate gel depot 1histrelin 1genistein combined polysaccharide 1fluciclovine F-18 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Prostatic Neoplasms × Celecoxib × Clear all
NCT00268476 2023-04-18

STAMPEDE

Medical Research Council

Phase 2/3 Active not recruiting
11,992 enrolled
Genitourinary

Prostatic Neoplasms

NCT00136487 2009-12-09

Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer

Dana-Farber Cancer Institute

Phase 2/3 Completed
85 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡